Development of live biotherapeutic products in the field of microbiota oncology.
EverImmune has raised €8.7M across 2 funding rounds from 2 investors, most recently a round in Sep 2023. Based in Villejuif, France; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2023-09-19 | Other | €3.5M | Bpifrance | View deal → |
| 2021-11-30 | Series A | €5.3M | Private Investors | View deal → |
